Almirall: enters into licensing agreement in China

(CercleFinance.com) - Alongside its 2019 earnings report on Monday, Spanish biopharmaceutical company Almirall said that it has entered into a licensing deal to develop its acne drug in China.


Under the terms of an agreement with Paratek, Almirall will be responsible for the development and marketing of the product in China in exchange for royalties calculated as a percentage of net sales once the product is launched onto the market.

The oral antibiotic for the treatment of moderate-to-severe acne is expected to be submitted for filing in China in 2023.

Almirall has been marketing the drug in the US since January 2019, following the acquisition of the US medical dermatology portfolio from Allergan.

Copyright (c) 2020 CercleFinance.com. All rights reserved.